Trial Profile
ROSY-D: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab and Are Judged by the Investigator to Clinically Benefit From Continued Treatment
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 20 Apr 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary)
- Indications Non-small cell lung cancer; Urogenital cancer
- Focus Adverse reactions; Registrational
- Acronyms ROSY-D
- Sponsors AstraZeneca; AstraZeneca AB
- 27 Nov 2023 Planned End Date changed from 17 Jun 2024 to 8 May 2025.
- 27 Nov 2023 Planned primary completion date changed from 17 Jun 2024 to 8 May 2025.
- 12 Sep 2023 Planned number of patients changed from 68 to 175.